摘要
目的观察重组改构人肿瘤坏死因子(rhmTNF)联合博来霉素(BLM)胸腔灌注治疗肺癌恶性胸腔积液的近期疗效及毒副反应。方法收集2007年6月至2010年10月112例肺癌伴恶性胸腔积液患者,经胸腔置中心静脉导管排尽胸腔积液后分为3组。rhmTNF组32例胸腔内灌注rhmTNF 200万～300万单位,BLM组41例胸腔内灌注BLM 40～60mg,联合组39例胸腔内联合灌注rhmTNF 200万～300万单位和BLM 40～60mg。3组患者均每周治疗2次,共4次。治疗后1个月观察近期疗效、毒副反应及KPS评分改善情况。结果 rhmTNF组、BLM组和联合组的有效率分别为46.9%、46.3%和82.1%,联合组显著高于其他两组(P<0.05)。3组主要毒副反应为发热及胸痛,3组间差异无统计学意义(P>0.05)。rhmT-NF组、BLM组和联合组KPS评分改善率分别为53.1%、51.2%和84.6%,联合组显著高于其他两组,差异有统计学意义(P<0.05)。结论 rhmTNF联合BLM胸腔灌注治疗肺癌恶性胸腔积液有效、安全,值得推广。
Objective To observe the efficacy and toxicity of recombinant mutant human tumor necrosis factor（rmhTNF） and bleomycin（BLM） on patients with malignant pleurisy effusion caused by lung cancer. Methods One hundred and twelve patients with malignant pleural effusion caused by lung cancer enrolled from June 2007 to October 2010 were divided into three groups.Group rmhTNF was intra-pleurally infused with 2-3 million units of rmhTNF.Group BLM was infused with 40-60mg of BLM.Group rmhTNF＋BLM was infused with 2-3 million units of rmhTNF and 40-60mg of BLM.Each patient was treated twice a week for 2 weeks.One month after treatment,the efficacy,toxicity and KPS score were evaluated. Results The effective rate in group rmhTNF,group BLM and group rmhTNF＋BLM were 46.9%,46.3% and 82.1%.Group rmhTNF＋BLM was much higher than the other two groups with statistic significance（P0.05）.The main toxicities were fever and chest pain,but no significant difference was found among the three groups（P0.05）.The improvement rate of KPS in group rmhTNF and group BLM were 53.1% and 51.2%,while that in group rmhTNF＋BLM was 84.6% which were higher than the other two groups（P0.05）. Conclusion rmhTNF combined with BLM is efficient and safe for malignant pleural effusion which deserves further application.
出处
《临床肿瘤学杂志》
CAS
2011年第12期1104-1107,共4页
Chinese Clinical Oncology
关键词
重组改构人肿瘤坏死因子
博来霉素
肺癌
恶性胸腔积液
Recombinant mutant human tumor necrosis factor
Bleomycin
Lung cancer
Malignant pleural effusion
